Browsing by Author Moore, Melissa

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 8 of 8
Issue DateTitleAuthor(s)Citation
2012Activation of Thermogenesis in Brown Adipose Tissue and Dysregulated Lipid Metabolism Associated with Cancer Cachexia in MiceClarke, Stephen; Robertson, Graham; Burg, Dominic; Cooney, Gregory; Lockie, Sarah; Moore, Melissa; Oldfield, Brian J; Painter, Arran; Taylor, Ryland; Tsoli, Maria; Turner, Nigel; Warren, Alessandra; Northern Clinical School: Kolling Institute; Concord Clinical School: ANZAC Research InstituteActivation of Thermogenesis in Brown Adipose Tissue and Dysregulated Lipid Metabolism Associated with Cancer Cachexia in Mice, Cancer Research, vol.72, 17, 2012,pp 4372-4382
2011Clinical, laboratory and molecular factors predicting chemotherapy efficacy and toxicity in colorectal cancerCharles (nee Slaviero), Kellie; Chua, Wei; Clarke, Stephen; Kho, Patricia; Moore, Melissa; School of Medical Sciences: Pharmacology; Concord Clinical School: Medicine; Northern Clinical School: Kolling Institute; Concord Clinical School: Medicine; Concord Clinical School: MedicineClinical, laboratory and molecular factors predicting chemotherapy efficacy and toxicity in colorectal cancer, Critical Reviews in Oncology / Hematology, vol.79, 3, 2011,pp 224-250
2012Disruption of MEF2C signaling and loss of sarcomeric and mitochondrial integrity in cancer-induced skeletal muscle wastingClarke, Stephen; Moore, Melissa; Painter, Arran; Polly, Patsie; Robertson, Graham; Shum, Angie; Taylor, Ryland; Tsoli, Maria; Mahendradatta, Theodore; Tan, T.C.; Concord Clinical School: Medicine; Concord Clinical School: Medicine; Concord Clinical School: ANZAC Research Institute; Concord Clinical School: ANZAC Research Institute; Concord Clinical School: ANZAC Research Institute; Concord Clinical School: ANZAC Research Institute; Concord Clinical School: ANZAC Research Institute; Concord Clinical School: ANZAC Research InstituteDisruption of MEF2C signaling and loss of sarcomeric and mitochondrial integrity in cancer-induced skeletal muscle wasting, Aging, vol.4, 2, 2012,pp 133-143
2009Ethnic differences in drug metabolism and toxicity from chemotherapyClarke, Stephen; McLachlan, Andrew; Xu, Hongmei; Hong, Phan; Moore, Melissa; Piquette-Miller, Micheline; Northern Clinical School: Kolling Institute; Pharmacy; PharmacyEthnic differences in drug metabolism and toxicity from chemotherapy, Expert Opinion on Drug Metabolism and Toxicology, vol.5, 3, 2009,pp 243-257
2010Is it Prime Time for Personalized Medicine in Cancer Treatment?Chua, Wei; Clarke, Stephen; Kho, Patricia; Moore, Melissa; Concord Clinical School: Medicine; Concord Clinical School: ANZAC Research Institute; Concord Clinical School: Medicine; Concord Clinical School: MedicineIs it Prime Time for Personalized Medicine in Cancer Treatment?, Personalized Medicine, vol.7, 4,pp 387-397
2010A phase II study of fenretinide in patients with hormone refractory prostate cancer: a trial of the Cancer Therapeutics Research GroupBoyer, Michael; Moore, Melissa; Stockler, Martin; Lim, Robert; Millward, Michael; Mok, T. S. K.; Central Clinical School: Medicine; Concord Clinical School: Medicine; NH&MRC Clinical Trials CentreA phase II study of fenretinide in patients with hormone refractory prostate cancer: a trial of the Cancer Therapeutics Research Group, Cancer Chemotherapy and Pharmacology, vol.66, 5, 2010,pp 845-850
2009Predictive biomarkers of clinical response to targeted antibodies in colorectal cancer.Charles (nee Slaviero), Kellie; Chua, Wei; Clarke, Stephen; Moore, Melissa; School of Medical Sciences: Pharmacology; Concord Clinical School: Medicine; Concord Clinical School: ANZAC Research InstitutePredictive biomarkers of clinical response to targeted antibodies in colorectal cancer., Current Opinion in Molecular Therapeutics, vol.11, 6,pp 611-622
2009Third-line Treatment Options for Metastatic Colorectal CancerBeale, Philip; Chua, Wei; Clarke, Stephen; Moore, Melissa; Central Clinical School: Medicine; Concord Clinical School: Medicine; Concord Clinical School: ANZAC Research Institute; Western Clinical School: Medicine (Westmead)Third-line Treatment Options for Metastatic Colorectal Cancer, Asia Pacific Journal of Oncology & Hematology, vol.1,(1),2009,pp 27-35